vs
Side-by-side financial comparison of NovaBay Pharmaceuticals, Inc. (NBY) and Satellogic Inc. (SATL). Click either name above to swap in a different company.
Satellogic Inc. is the larger business by last-quarter revenue ($6.2M vs $4.8M, roughly 1.3× NovaBay Pharmaceuticals, Inc.). Satellogic Inc. runs the higher net margin — 488.0% vs -25.5%, a 513.5% gap on every dollar of revenue. NovaBay Pharmaceuticals, Inc. produced more free cash flow last quarter ($-1.7M vs $-12.8M).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
Satellogic Inc. is an American company specializing in Earth-observation satellites, founded in 2010 by Emiliano Kargieman and Gerardo Richarte.
NBY vs SATL — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $6.2M |
| Net Profit | $-1.2M | $30.5M |
| Gross Margin | 65.2% | — |
| Operating Margin | -37.2% | -114.2% |
| Net Margin | -25.5% | 488.0% |
| Revenue YoY | 126.1% | — |
| Net Profit YoY | 70.5% | — |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $6.2M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $3.4M | ||
| Q4 24 | $4.8M | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $2.4M | $3.5M | ||
| Q1 24 | $2.6M | — |
| Q4 25 | — | $30.5M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $-6.7M | ||
| Q1 25 | — | $-32.6M | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-1.6M | $-18.1M | ||
| Q1 24 | $-3.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 65.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 66.3% | — | ||
| Q1 24 | 68.2% | — |
| Q4 25 | — | -114.2% | ||
| Q3 25 | — | -222.5% | ||
| Q2 25 | — | -141.6% | ||
| Q1 25 | — | -280.9% | ||
| Q4 24 | -37.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -67.4% | -419.2% | ||
| Q1 24 | -87.1% | — |
| Q4 25 | — | 488.0% | ||
| Q3 25 | — | 109.2% | ||
| Q2 25 | — | -149.8% | ||
| Q1 25 | — | -961.9% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -66.0% | -517.0% | ||
| Q1 24 | -122.2% | — |
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.34 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.92 | — | ||
| Q2 24 | $-1.37 | $-0.20 | ||
| Q1 24 | $-29.95 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $430.0K | $94.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-129.0K | $60.5M |
| Total Assets | $3.4M | $151.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $94.4M | ||
| Q3 25 | — | $28.3M | ||
| Q2 25 | — | $32.6M | ||
| Q1 25 | — | $17.7M | ||
| Q4 24 | $430.0K | — | ||
| Q3 24 | $776.0K | — | ||
| Q2 24 | $751.0K | $25.6M | ||
| Q1 24 | $1.8M | — |
| Q4 25 | — | $60.5M | ||
| Q3 25 | — | $-56.9M | ||
| Q2 25 | — | $-68.1M | ||
| Q1 25 | — | $-83.1M | ||
| Q4 24 | $-129.0K | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $-617.0K | $19.1M | ||
| Q1 24 | $160.0K | — |
| Q4 25 | — | $151.3M | ||
| Q3 25 | — | $70.9M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $61.4M | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $3.9M | — | ||
| Q2 24 | $3.9M | $76.6M | ||
| Q1 24 | $5.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-9.5M |
| Free Cash FlowOCF − Capex | $-1.7M | $-12.8M |
| FCF MarginFCF / Revenue | -35.4% | -204.9% |
| Capex IntensityCapex / Revenue | 0.1% | 53.6% |
| Cash ConversionOCF / Net Profit | — | -0.31× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-34.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-9.5M | ||
| Q3 25 | — | $-8.4M | ||
| Q2 25 | — | $-4.3M | ||
| Q1 25 | — | $-4.7M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | — | $-12.8M | ||
| Q3 25 | — | $-9.7M | ||
| Q2 25 | — | $-5.1M | ||
| Q1 25 | — | $-6.6M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.0M | — |
| Q4 25 | — | -204.9% | ||
| Q3 25 | — | -267.2% | ||
| Q2 25 | — | -115.3% | ||
| Q1 25 | — | -195.9% | ||
| Q4 24 | -35.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -75.3% | — |
| Q4 25 | — | 53.6% | ||
| Q3 25 | — | 36.8% | ||
| Q2 25 | — | 17.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | -0.31× | ||
| Q3 25 | — | -2.11× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
SATL
| Transferred At Point In Time | $5.7M | 91% |
| Other | $547.0K | 9% |
